Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of inosine in preparation of medicine for preventing decompression sickness caused by rapid ascent and escape

A technology for decompression sickness and inosine, which is applied in drug delivery, drug combination, and pharmaceutical formulations, etc., can solve problems that have not been confirmed by research, and achieve the effects of improving survival rate, reducing lung damage and inflammation, and relieving symptoms

Active Publication Date: 2018-01-16
NAVY MEDICINE RES INST OF PLA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have confirmed that this molecule can be applied to the prevention of decompression sickness caused by rapid surfacing and escape

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of inosine in preparation of medicine for preventing decompression sickness caused by rapid ascent and escape
  • Application of inosine in preparation of medicine for preventing decompression sickness caused by rapid ascent and escape
  • Application of inosine in preparation of medicine for preventing decompression sickness caused by rapid ascent and escape

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Injection drug for experiment: Inosine was formulated into 12.5mg / ml, 50mg / ml and 100mg / ml suspension solutions with physiological saline, and prepared into injections.

[0025] Experimental animals and grouping: 80 male healthy Wistar rats, weighing 220-260 g, were purchased from Shanghai Slack Experimental Animal Co., Ltd. Wistar rats were randomly divided into inosine 25mg / kg prevention group, inosine 100mg / kg prevention group, inosine 200mg / kg prevention group and normal saline control group, 20 rats in each group.

[0026] Experimental method: 30 minutes before pressurization in the prevention group, intraperitoneal injection of inosine solution (injection doses were 25 mg / kg, 100 mg / kg and 200 mg / kg), and 30 minutes before pressurization in the control group, an equal volume of normal saline was injected intraperitoneally , and then put the experimental animals in the pressurized chamber for rapid escaping and escape, close the door, and use a self-programmed comp...

Embodiment 2

[0035] Injection drug for experiment: use normal saline to make inosine into 100mg / ml suspension solution, and make injection. AZD6244 is first made into 200mg / ml mother solution with DMSO, and then diluted with normal saline to 50mg / ml working solution.

[0036] Experimental animals and grouping: 60 healthy male Wistar rats, weighing 220-260 g, were purchased from Shanghai Slack Experimental Animal Co., Ltd. Wistar rats were randomly divided into inosine prevention group (200mg / kg), AZD6244 pretreatment group (100mg / kg) and normal saline control group, 20 rats in each group.

[0037] Experimental method: 30 minutes before treatment in the inosine prevention group, intraperitoneal injection of inosine solution, 30 minutes before treatment of AZD6244 solution and normal saline control group, intraperitoneal injection of an equal volume of normal saline, and then the experimental animals were placed in a rapid floating escape chamber. Ballast the cabin, close the cabin door, use t...

Embodiment 3

[0041] Injection drug for experiment: use normal saline to make inosine into 100mg / ml suspension solution, and make injection. AZD6244 is first made into 200mg / ml mother solution with DMSO, and then diluted with normal saline to 50mg / ml working solution.

[0042] Experimental animals and grouping: 60 healthy male Wistar rats, weighing 220-260 g, were purchased from Shanghai Slack Experimental Animal Co., Ltd. Wistar rats were randomly divided into inosine prevention group (200mg / kg), inosine (200mg / kg)+AZD6244 pretreatment group (100mg / kg) and normal saline control group, 20 rats in each group.

[0043] Experimental method: the inosine prevention group and the inosine+AZD6244 solution group were injected with inosine solution or inosine+AZD6244 solution 30 minutes before treatment, and the normal saline control group was injected with an equal volume of normal saline 30 minutes before treatment. , and then put the experimental animals in the pressurized chamber for rapid escap...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine preparation, and in particular relates to application of inosine in preparing a medicine for preventing decompression sickness caused by fast buoyancy ascent escape. The inosine is dissolved in normal saline, so that an injection with concentration ranging from 25mg / mL to 125mg / mL is prepared for use. For intraperitoneal injection, the dosage of the inosine is 50-250mg / kg. The inosine is applied 25-35min before the fast buoyancy ascent escape. Upon experiments, the inosine can significantly relieve lung injury and inflammation, so that pathologic change caused by the decompression sickness is relieved and lung functions are improved; and the inosine can inhibit heart failure caused by edema and breakage of cardiac muscle fibers due to the existence of bubbles. Moreover, the invention provides experimental data for the more reasonable application of the inosine to the prevention of decompression sickness caused by fast buoyancy ascent escape in the clinical field.

Description

technical field [0001] The invention belongs to the field of medicine preparation, and particularly relates to the application of inosine in the preparation of medicines for preventing decompression sickness caused by rapid ascent and escape. Background technique [0002] As one of the main methods for underwater escape of submarine crews generally adopted by the navies of various countries, fast surfacing is to use the principle of no-decompression diving to make the crew escape from the wrecked ship at a large depth. Because of its advantages such as simple equipment, easy method, large escape depth and simple operation, it has been adopted by many countries. However, as the depth deepens, the high-pressure exposure time allowed by the crew is quite limited. If the exposure time is too long due to improper pressure adjustment and other reasons, severe decompression sickness will occur. [0003] Recompression therapy is generally adopted for the treatment of common decompr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7076A61P11/00A61P9/04A61P43/00
CPCA61K9/0019A61K9/08A61K31/7076
Inventor 攸璞方以群沈泉包晓辰马骏王世锋刘平小张师
Owner NAVY MEDICINE RES INST OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com